PC11 - Advancing Viral Hepatitis Screening and Treatment in Opioid Treatment Settings – Models & Resources

Sunday, May 19, 2024

9:00 AM – 12:30 PM PST

Location: Melrose 3

CE: 3.5

Moderator(s)

Zakiya Grubbs, MPH (she/her/hers)

Manager, Hepatitis
NASTAD
Washington, District of Columbia

Pre-Conference Speaker(s)

Andrew Talal, MD, MPH

Professor, Department of Medicine
University of Buffalo, Jacobs School of Medicine & Biomedical Sciences
Buffalo, New York

Download Slides Handouts
Lawrence S. Brown, Jr., MD (he/him/his)

Clinical Associate Professor of Medicine
Weill Cornell Medical College
Brooklyn, New York

Download Slides
Raktim Mukhopadhyay, MS (he/him/his)

PhD Student
University at Buffalo
Buffalo, New York

Download Slides
Marianthi Markatou, PhD

SUNY Distinguished Professor
University at Buffalo
Buffalo, New York

Download Slides
Arpan Dharia, MD (he/him/his)

Director of Liver Services
University at Buffalo
Buffalo, New York

Download Slides
Kenneth E. Bossert, CASAC (he/him/his)

Program Administrator
Community Action Organization of Western New York Inc (Retired)
Lake View, New York

Download Slides
Elisabeth Houtsmuller, PhD (she/her/hers)

Program Director
Research Triangle Institute
Baltimore, Maryland

Download Slides

Pre-Conference Planner(s)

Andrew Talal, MD, MPH

Professor, Department of Medicine
University of Buffalo, Jacobs School of Medicine & Biomedical Sciences
Buffalo, New York

Download Slides Handouts
Boatemaa Nitri-Reid, JD, MPH (she/her/hers)

Senior Director, Syndemic Approaches
NASTAD
Washington , District of Columbia

Presentation Summary: This session is designed to highlight models and resources for facilitated telemedicine to screen for and treat HCV in opioid treatment settings. Participants in this session will learn about opportunities to partner with public health, infectious disease, and other clinical partners to advance hepatitis screening, models for implementation of facilitated telemedicine to treat HCV, and resources designed to support infectious disease services in these settings.

Learning Objectives:

At the completion of this activity, participants will:

Assess the effectiveness of facilitated telemedicine for hepatitis C virus elimination.
Describe the decreases in substance use after HCV cure.
Compare HCV reinfection rates between participants treated through facilitated telemedicine compared to referral.